Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970930 · ClinicalTrials.gov registry record
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 131
- Enrollment target
NCT01970930: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01970930 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 131 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01970930 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 131 participants
- Enrollment target
Study Summary
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.
Primary Outcome
Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
Interventions
- PROCEDURE Blood specimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-06-02 |
What the finished NCT01970930 record still lists
NCT01970930 is an observational study that tracks outcomes without assigning an intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood specimen is the first listed.
NCT01970930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01970930 about?
NCT01970930 is a clinical study titled "Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients". The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.
What is the current status of trial NCT01970930?
This trial is currently completed. The enrollment target is 131 participants. The study started on 2012-08. Estimated completion is 2016-06-02.
What interventions are being tested in trial NCT01970930?
The interventions under investigation include: Blood specimen (PROCEDURE).
Who is sponsoring clinical trial NCT01970930?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia